Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSBM6A)

Drug Name

BNC-101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Metastatic colorectal cancer	2B91	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leucine-rich repeat-containing GPCR 5 (LGR5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MCLA-158	DMF0O3X	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
BNC-102	DMM1O0P	Solid tumour/cancer	2A00-2F9Z	Preclinical	[4]
KM-4056	DMK17GN	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leucine-rich repeat-containing GPCR 5 (LGR5)	TTTSGRH	LGR5_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Bionomics.
3	Clinical pipeline report, company report or official report of Merus.
4	Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 148).